Skip to main content

Table 3 Primary and secondary outcomes of the included articles

From: A meta-analysis of the watch-and-wait strategy versus total mesorectal excision for rectal cancer exhibiting complete clinical response after neoadjuvant chemoradiotherapy

Study

LR (n/%)

DM (n/%)

CRD (n/%)

2-year OS (n/%)

2-year DFS (n/%)

 

W&W

TME

W&W

TME

W&W

TME

W&W

TME

W&W

TME

Ayloor[16]

7(30.13%)

0

3(13.04%)

2(20%)

NR

NR

NR

NR

NR

NR

Dalton[17]

NR

NR

NR

NR

NR

NR

6(100%)

6(100%)

6(100%)

6(100%)

Habr[18]

2(2.81%)

0

3(4.22%)

3(13.6%)

0

2(9.09%)

71(100%)

20(90.9%)

70(98.59%)

19(86.36%)

Lai[19]

2(11.11%)

0

0

1(3.84%)

NR

NR

18(100%)

26(100%)

NR

NR

Li[20]

2(6.66%)

2(2.17%)

1(3.33%)

5(5.43%)

0

4(4.34%)

30(100%)

92(100%)

29(96.66%)

91(98.91%)

Mass[21]

1(4.76%)

0

0

1(5%)

NR

NR

21(100%)

19(95%)

19(90.47%)

19(95%)

Smith[22]

1(5.55%)

0

1(5.55%)

1(3.33%)

NR

NR

17(100%)

30(100%)

16(94.11%)

29(96.66%)

Wang[23]

7(11.86%)

1(0.56%)

6(10.16%)

17(9.49%)

NR

NR

NR

NR

NR

NR

Wang[24]

14(14.89%)

1(1.06%)

20(21.27%)

11(11.7%)

4(4.2%)

6(6.3%)

NR

NR

NR

NR

Total

36(10.81%)

4(0.84%)

34(10.21%)

41(8.66%)

4(2.1%)

12(5.76%)

163(100%)

193(98.4%)

140(96.55%)

164(96.47%)

Study

3-year OS (n/%)

3-year DFS (n/%)

5-year OS (n/%)

5-year DFS (n/%)

 

W&W

TME

W&W

TME

W&W

TME

W&W

TME

Ayloor[16]

NR

NR

NR

NR

NR

NR

NR

NR

Dalton[17]

NR

NR

NR

NR

NR

NR

NR

NR

Habr[18]

NR

NR

NR

NR

71(100%)

20(90.90%)

68(95.77%)

19(86.36%)

Lai[19]

NR

NR

NR

NR

18(100%)

24(92.30%)

NR

NR

Li[20]

NR

NR

NR

NR

30(100%)

88(95.65%)

27(90%)

85(92.39%)

Mass[21]

21(100%)

19(95%)

20(95.2%)

19(95%)

NR

NR

NR

NR

Smith[22]

17(100%)

29(96.66%)

15(88.23%)

29(96.66%)

17(100%)

29(96.66%)

15(88.23%)

29(96.66%)

Wang[23]

59(100%)

175(97.9%)

NR

NR

53(89.83%)

175(97.76%)

NR

NR

Wang[24]

93(99%)

90(96%)

93(99%)

89(95%)

NR

NR

NR

NR

Total

190(99.47%)

313(96.9%)

128(96.96%)

137(95.14%)

189(96.92%)

336(96.28%)

110(93.22%)

133(92.36%)

  1. Notes: LR: local recurrence; DM: distant metastasis; CRD:cancer related death; DFS: disease free survival; OS: overall survival; NR:no record